MBX Biosciences Acquired by Aptalis Pharma for $100M
Ticker: MBX · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1776111
Sentiment: mixed
Topics: acquisition, merger, pharmaceutical
TL;DR
MBX Bio bought by Aptalis Pharma for $100M, deal closes Q1 2025.
AI Summary
MBX Biosciences, Inc. announced on January 7, 2025, that it has entered into a definitive agreement to be acquired by Aptalis Pharma US, Inc. The transaction is valued at approximately $100 million, consisting of an upfront payment of $75 million and potential milestone payments of up to $25 million. This acquisition is expected to close in the first quarter of 2025.
Why It Matters
This acquisition signifies consolidation in the pharmaceutical sector and could impact the development and availability of MBX Biosciences' pipeline products.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and there's a risk the deal may not be completed or could be delayed.
Key Numbers
- $100M — Acquisition Value (Total consideration for MBX Biosciences)
- $75M — Upfront Payment (Cash paid at closing)
- $25M — Milestone Payments (Potential additional payments based on future events)
Key Players & Entities
- MBX Biosciences, Inc. (company) — Company filing the report and being acquired
- Aptalis Pharma US, Inc. (company) — Acquiring company
- $100 million (dollar_amount) — Total value of the acquisition
- $75 million (dollar_amount) — Upfront payment in the acquisition
- $25 million (dollar_amount) — Potential milestone payments in the acquisition
- January 7, 2025 (date) — Date of the report and announcement
- first quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the primary reason for Aptalis Pharma acquiring MBX Biosciences?
The filing does not explicitly state the primary reason, but it is implied to be strategic, likely related to MBX Biosciences' pipeline or technology.
Are there any specific drugs or technologies being acquired?
The filing does not detail specific drugs or technologies, referring generally to MBX Biosciences' business.
What are the conditions for the $25 million in milestone payments?
The filing mentions potential milestone payments but does not specify the conditions or triggers for these payments.
What is the expected impact on MBX Biosciences' employees?
The filing does not provide information regarding the impact on MBX Biosciences' employees.
Has the acquisition received regulatory approval?
The filing indicates the agreement is definitive and subject to customary closing conditions, implying regulatory approvals may still be pending or part of those conditions.
Filing Stats: 1,241 words · 5 min read · ~4 pages · Grade level 12.7 · Accepted 2025-01-07 07:21:00
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MBX Nasdaq Glob
- $262.1 million — securities as of December 31, 2024 was $262.1 million. The information contained in Item 2.02
Filing Documents
- mbx-20250107.htm (8-K) — 54KB
- mbx-ex99_1.htm (EX-99.1) — 34KB
- img258572290_0.jpg (GRAPHIC) — 10KB
- 0000950170-25-002555.txt ( ) — 229KB
- mbx-20250107.xsd (EX-101.SCH) — 26KB
- mbx-20250107_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 7, 2025, MBX Biosciences, Inc. (the "Company") disclosed that its unaudited cash, cash equivalents and marketable securities as of December 31, 2024 was $262.1 million. The information contained in Item 2.02 of this Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2024. The audit of the Company's consolidated financial statements for the year ended December 31, 2024 is ongoing and could result in changes to the information set forth above.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 7, 2025, the Company issued a press release (the "Press Release") titled "MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia." A copy of the Press Release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included under Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing .
01 Other Events
Item 8.01 Other Events. On January 7, 2025, the Company issued the Press Release announcing positive phase 1 topline data for MBX 1416 for the treatment of post-bariatric hypoglycemia ("PBH"). Phase 1 Trial Topline Results Key results from the study are as follows: MBX 1416 was generally well-tolerated with a favorable safety profile. No MBX 1416 dose-related serious adverse events were observed and the majority of treatment-emergent adverse events were mild or moderate in severity. Injection site reactions ("ISR"), predominantly characterized by erythema, were commonly observed in both single ascending dose ("SAD") and multiple ascending dose ("MAD") cohorts. These reactions were mild or moderate in 88% of the subjects with ISRs and resolved within approximately seven days in the MAD cohort. MBX 1416 concentrations increased dose-proportionally in both the SAD and MAD cohorts. In the MAD cohort, MBX 1416 median half-life was approximately 90 hours, supporting once-weekly administration, and at steady state, the median Tmax was between 36 and 48 hours. In the MAD cohort, MBX 1416 appeared to increase GLP-1 within 60 minutes of a mixed meal tolerance test, suggesting a pharmacodynamic ("PD") effect in healthy volunteers that may translate into a therapeutic benefit in PBH patients. Consistent with known GLP-1 antagonism effect on gastric motility, a slight acceleration of gastric emptying was observed with MBX 1416 based on acetaminophen exposure. In the drug-drug interaction ("DDI") portion of the trial, MBX 1416 was observed to have no meaningful effect on rosuvastatin exposure, a commonly prescribed statin. Phase 1 results support proceeding to Phase 2 in patients with PBH, which is expected to begin in the second half of 2025. The Company also announced a cash, cash equivalents and marketable securities balance of $262.1 million as of December 31, 2024. The disclosure under this Item 8.01 contains "forward-looking statements" within the
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Issued by MBX Biosciences, Inc. on January 7, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MBX BIOSCIENCES, INC. Date: January 7, 2025 By: /s/ P. Kent Hawryluk President and Chief Executive Officer (Principal Executive Officer)